ARTICANZ - Beta (ver 0.91)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - catype/medical-oncology/cervical/metastatic
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
Gynaecological / Cervical - Metastatic
15
trial(s) found.
NCT07070232
Advanced
Phase 1 / Phase 2
Recruiting
A Phase I/II, Open-label, Adaptive Two-part Trial to Evaluate the Safety, Efficacy, Optimal Dose and Pharmacokinetics of BNT326 as Monotherapy and in Combination With Cancer Immunotherapies in Participants With Advanced Solid Tumors (
BNT326-01
)
Itraconazole
Pumitamig
SMO inhibitor
bispecific PD-L1/VEGFA antibody
cancer therapy
cancer therapy,PD-1/PD-L1-targeting
cancer therapy,PD-L1-targeting
cancer therapy,SMO-targeting
cancer therapy,VEGFA-targeting
immune checkpoint blockade
immune checkpoint blockade,PD-L1-targeting
immuno-oncology therapy,PD-L1-targeting
immuno-oncology therapy,VEGFA-targeting
Breast cancer
Cervical cancer
Colorectal adenocarcinoma
Gastroesophageal junction adenocarcinoma
Melanoma
Mucosal melanoma
Non-small cell lung cancer
Solid tumour
Uveal melanoma
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2065 - Wollstonecraft - Melanoma Institute Australia - The Poche Centre
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
VIC
3004 - Melbourne, Southbank - Alfred Health
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
QLD
4215 - Southport - Tasman Oncology
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6009 - Nedlands - One Clinical Research
NCT06953089
Advanced
Phase 2
Recruiting
A Phase II, Multicenter, Open-Label Trial of DB-1311 in Combination With BNT327 or DB-1305 in Participants With Advanced/Metastatic Solid Tumors (
DB-1311-201
)
anti-B7H3 antibody-drug conjugate
anti-Trop2 antibody-drug conjugate
Cervical cancer
Head and neck squamous cell carcinoma
Hepatocellular carcinoma
Melanoma
Non-small cell lung cancer
Ovarian cancer
NSW
2060 - North Sydney - Mater Hospital
QLD
4217 - Benowa - Pindara Private Hospital
4575 - Birtinya - Sunshine Coast University Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
NCT06910657
Advanced
Phase 1
Recruiting
A First-in-human, Phase I, Multi-center, Open-label, Dose-escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Evidence of Antitumor Activity of IDOV-Immune in Adult Participants With Advanced Solid Tumors (
VM-002-101
)
oncolytic virus,undisclosed mechanism
Bladder cancer
Breast cancer
Cancer
Cervical cancer
Clear cell renal cell carcinoma
Colorectal cancer
Gastric cancer
Head and neck cancer
Hepatocellular carcinoma
Lung cancer
Melanoma
Oesophageal cancer
Ovarian cancer
Pancreatic cancer
Prostate cancer
Sarcoma
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3004 - Melbourne, Southbank - Alfred Health
NCT06760819
Advanced
Phase 2
Recruiting
A Phase 2 Open-label Basket Study to Evaluate the Efficacy and Safety of Orally Administered Reversible Tyrosine Kinase Inhibitor BAY 2927088 in Participants With Metastatic or Unresectable Solid Tumors With HER2-activating Mutations (
panSOHO
)
EGFR/ERBB2 inhibitor,mutant-selective,non-covalent
Breast cancer
Cervical cancer
Colorectal adenocarcinoma
Endometrial cancer
NOT Biliary tract cancer
NOT Colorectal cancer
NOT Non-small cell lung cancer
NOT Urothelial carcinoma
Urothelial carcinoma
NSW
2109 - North Ryde - Macquarie University Hospital
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
QLD
4215 - Southport - ICON Cancer Care
NCT06581432
Advanced
Phase 2
Recruiting
Beamion PANTUMOR-1: A Phase II, Multicentre, Multicohort, Open-label Trial to Evaluate the Efficacy and Safety of Oral Zongertinib (BI 1810631) for the Treatment of Selected HER2-mutated or Overexpressed/Amplified Solid Tumours (
1479-0009
)
ERBB2 inhibitor,second generation
Cervical cancer
Gastroesophageal junction adenocarcinoma
NOT Breast cancer
NOT Colorectal adenocarcinoma
NOT Gastroesophageal cancer
NOT Pancreatic adenocarcinoma
NOT Pancreatic cancer
NOT Squamous non-small-cell lung cancer
Non-small cell lung cancer
Solid tumour
Urothelial carcinoma
NSW
2065 - St Leonards - GenesisCare North Shore Private Hospital
2109 - North Ryde - Macquarie University Hospital
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital
NCT06535607
Advanced
Phase 2
Recruiting
A Phase II, Multi-Center Study to Evaluate the Efficacy and Safety of Volrustomig as Monotherapy or in Combination With Anti-cancer Agents in Participants With Advanced/Metastatic Solid Tumors (
eVOLVE-02
)
bispecific PD-L1/CTLA4 antibody
Cervical cancer
Head and neck squamous cell carcinoma
Oesophageal squamous cell carcinoma
Pleural mesothelioma
VIC
3168 - Clayton - Monash Medical Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT06465069
Advanced
Phase 1
Recruiting
A Phase 1a/1b Study of LY4052031, an Antibody-Drug Conjugate Targeting Nectin-4, in Participants With Advanced or Metastatic Urothelial Carcinoma or Other Solid Tumors (
NEXUS-01
)
anti-NECTIN4 antibody-drug conjugate
Bladder cancer
Cervical cancer
Head and neck squamous cell carcinoma
Non-small cell lung cancer
Oesophageal cancer
Ovarian cancer
Pancreatic cancer
Prostate cancer
Renal pelvis cancer
Solid tumour
Triple-negative breast cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
WA
6009 - Nedlands - Linear Clinical Research
NCT06400472
Advanced
Phase 1
Recruiting
A First-in-Human, Phase 1a/1b Trial to Assess the Safety, Tolerability and Preliminary Efficacy of LY4170156, an Antibody-Drug Conjugate Targeting Folate Receptor α-Expressing Tumor Cells, in Participants With Selected Advanced Solid Tumors
anti-FR-alpha antibody-drug conjugate
Cervical cancer
Colorectal cancer
Endometrial cancer
Non-small cell lung cancer
Ovarian cancer
Pancreatic cancer
Triple-negative breast cancer
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
NCT06330064
Advanced
Phase 2
Recruiting
A Phase 1B/2 Pan-Tumor, Open-Label Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02) (
DS7300-203
)
anti-B7H3 antibody-drug conjugate
Breast cancer
Cervical cancer
Colorectal adenocarcinoma
Cutaneous melanoma
Endometrial cancer
Gastrooesophageal adenicarcoma
Head and neck squamous cell carcinoma
Hepatocellular carcinoma
NOT Sarcoma
Ovarian cancer
Pancreatic adenocarcinoma
Urothelial carcinoma
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2065 - St Leonards - GenesisCare North Shore Private Hospital
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
WA
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital
NCT06242470
Advanced
Phase 1
Recruiting
A Phase 1/1b First-in-Human, Open Label, Dose Escalation and Cohort Expansion Study of MGC026 in Participants With Advanced Solid Tumors (
CP-MGC026-01
)
anti-B7H3 antibody-drug conjugate
Bladder cancer
Breast cancer
Cancer
Castrate-resistant prostate cancer
Cervical cancer
Clear cell renal cell carcinoma
Colorectal cancer
Endometrial cancer
Gastric cancer
Gastroesophageal cancer
Head and neck squamous cell carcinoma
Hepatocellular carcinoma
Melanoma
Non-small cell lung cancer
Ovarian cancer
Pancreatic cancer
Platinum resistant ovarian cancer
Sarcoma
Small-cell lung cancer
Solid tumour
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
QLD
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital
SA
5037 - Kurralta Park - Icon Cancer Centre Adelaide
NCT06172478
Advanced
Phase 2
Recruiting
HERTHENA-PanTumor01 (
U31402-277
): A Phase 2, Multicenter, Multicohort, Open-Label, Proof of Concept Study of Patritumab Deruxtecan (HER3-DXd; U3-1402) in Subjects With Locally Advanced or Metastatic Solid Tumors
anti-ERBB3 antibody-drug conjugate
Bladder cancer
Cervical cancer
Endometrial cancer
Gastric cancer
Gastroesophageal cancer
Head and neck squamous cell carcinoma
High-grade serous ovarian cancer
Melanoma
Oesophageal cancer
Pancreatic adenocarcinoma
Prostate adenocarcinoma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
VIC
3168 - Clayton - Monash Medical Centre
QLD
4032 - Chermside - Icon Cancer Care Chermside
4812 - Hyde Park - Icon Cancer Centre Townsville
TAS
7000 - Hobart - ICON Cancer Care Hobart
NCT06023862
Advanced
Phase 2
Recruiting
A Three-arm Randomized Phase II Study of Dostarlimab Alone or With Bevacizumab Versus Nonplatinum Chemotherapy in Recurrent Gynecological Clear Cell Carcinoma:
DOVE
(APGOT-OV07/ ENGOT-ov80 Study)
anti-VEGF monoclonal antibody
Cervical clear cell carcinoma
Endometrial clear cell carcinoma
Ovarian clear cell carcinoma
Vulval clear cell adenocarcinoma
NSW
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3168 - Clayton - Monash Medical Centre
NCT05086692
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2 Open Label, Dose Escalation and Expansion Study of MDNA11, IL-2 Superkine, Administered Alone or in Combination With Immune Checkpoint Inhibitor in Patients With Advanced Solid Tumors (
ABILITY-1
)
IL-2 superkine
Acral lentiginous melanoma
Bladder cancer
Cancer
Cervical cancer
Clear cell renal cell carcinoma
Colorectal cancer
Cutaneous basal cell carcinoma
Cutaneous melanoma
Cutaneous squamous cell carcinoma
Endometrial cancer
Endometrial carcinoma
Epithelial Ovarian Cancer
Fallopian tube cancer
Gastric cancer
Gastroesophageal junction adenocarcinoma
Head and neck squamous cell carcinoma
Melanoma
Merkel cell carcinoma
Mucosal melanoma
Non-melanoma skin cancer
Non-squamous non-small-cell lung cancer
Oesophageal cancer
Ovarian cancer
Pancreatic adenocarcinoma
Pleural mesothelioma
Primary peritoneal serous carcinoma
Skin cancer
Solid tumour
Squamous non-small-cell lung cancer
Triple-negative breast cancer
dMMR solid cancer
NSW
2031 - Randwick - Scientia Clinical Research Ltd
2109 - North Ryde - Macquarie University Hospital
QLD
4120 - Greenslopes - Greenslopes Private Hospital
4556 - Buderim - Sunshine Coast Haematology and Oncology Clinic
NCT04895709
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2 Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors (
CA052-002
)
anti-PD-1 monoclonal antibody
taxane
Cervical cancer
Clear cell renal cell carcinoma
Gastroesophageal junction adenocarcinoma
Head and neck squamous cell carcinoma
Melanoma
Microsatellite stable colorectal cancer
Non-small cell lung cancer
Ovarian cancer
Pancreatic adenocarcinoma
Triple-negative breast cancer
Urothelial carcinoma
NSW
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
2170 - Liverpool - Liverpool Hospital
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
WA
6009 - Nedlands - One Clinical Research
ACTRN12624000110583
Advanced
Not Applicable
Recruiting
SOCRATES PILOT: Standard of Care Randomised Treatment Evaluation Studies (
SOCRATES-PILOT
)
AR-targeted agent,next generation
AR-targeted agent,second generation
Abiraterone
Anastrozole
Apalutamide
Atorvastatin
Bevacizumab
CYP17A1 inhibitor
Darolutamide
Enzalutamide
HMG-CoA reductase inhibitor
Letrozole
Lomustine
Nab-paclitaxel
Niraparib
Olaparib
PARP1/2 inhibitor
PARP inhibitor
Paclitaxel
alkylating agent
anti-VEGF monoclonal antibody
antiandrogen
antiandrogen,nonsteroidal
antiandrogen,nonsteroidal,second generation
aromatase inhibitor
cancer therapy
cancer therapy,AR-targeting
cancer therapy,CYP17A1-targeting
cancer therapy,HMG-CoA reductase-targeting
cancer therapy,PARP-targeting
cancer therapy,VEGF-targeting
cytotoxic chemotherapy
endocrine therapy
endocrine therapy,androgen axis-targeting
endocrine therapy,oestrogen axis-targeting
immuno-oncology therapy,VEGF-targeting
oestrogen receptor-targeting therapy
taxane
Cervical cancer
Glioblastoma
Ovarian cancer
Prostate cancer
NSW
2031 - Randwick - Prince of Wales Hospital
2050 - Camperdown - Chris O'Brien Lifehouse
2139 - Concord - Concord Repatriation General Hospital
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (15)
Recruitment Country and State
NSW (12)
QLD (10)
VIC (7)
WA (6)
SA (5)
TAS (1)
Phase
Phase 1 (4)
Phase 1 / Phase 2 (3)
Phase 2 (7)
Trial Type
Advanced (15)
Cancer Therapy Class
PD-1/PD-L1
47%
PD-1
27%
PD-L1
20%
B7H3
20%
VEGF
20%
SMO
13%
VEGFA
13%
ERBB2
13%
Trop2
7%
EGFR
7%
CTLA4
7%
Nectin4
7%
FR-alpha
7%
ERBB3
7%
IL-2
7%
CCR8
7%
AR
7%
CYP17A1
7%
HMG-CoA reductase
7%
PARP
7%
androgen axis
7%
oestrogen axis
7%
Facility
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre (4)
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (4)
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre (3)
2109 - North Ryde - Macquarie University Hospital (3)
4102 - Woolloongabba - Princess Alexandra Hospital (3)
3168 - Clayton - Monash Medical Centre (3)
3004 - Melbourne, Southbank - Alfred Health (2)
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (2)
6009 - Nedlands - One Clinical Research (2)
2065 - St Leonards - GenesisCare North Shore Private Hospital (2)
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital (2)
2050 - Camperdown - Chris O'Brien Lifehouse (2)
2065 - Wollstonecraft - Melanoma Institute Australia - The Poche Centre (1)
4215 - Southport - Tasman Oncology (1)
2060 - North Sydney - Mater Hospital (1)
4217 - Benowa - Pindara Private Hospital (1)
4575 - Birtinya - Sunshine Coast University Hospital (1)
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital (1)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (1)
4215 - Southport - ICON Cancer Care (1)
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (1)
6009 - Nedlands - Linear Clinical Research (1)
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (1)
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital (1)
5037 - Kurralta Park - Icon Cancer Centre Adelaide (1)
4032 - Chermside - Icon Cancer Care Chermside (1)
4812 - Hyde Park - Icon Cancer Centre Townsville (1)
7000 - Hobart - ICON Cancer Care Hobart (1)
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (1)
3000 - Melbourne - Peter MacCallum Cancer Centre (1)
2031 - Randwick - Scientia Clinical Research Ltd (1)
4120 - Greenslopes - Greenslopes Private Hospital (1)
4556 - Buderim - Sunshine Coast Haematology and Oncology Clinic (1)
2170 - Liverpool - Liverpool Hospital (1)
3065 - Fitzroy - St Vincent's Hospital Melbourne (1)
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre (1)
2031 - Randwick - Prince of Wales Hospital (1)
2139 - Concord - Concord Repatriation General Hospital (1)
Cancer Type
Cancer
Cervical cancer
Gynaecological cancer
HPV-related cancer
HPV16-positive cancer
Solid tumour
Viral-related cancer
Gastrointestinal cancer
Upper gastrointestinal cancer
Thoracic cancer
Ovarian cancer
Urogenital cancer
Breast cancer
Gastroesophageal cancer
Lung cancer
Respiratory tract cancer
Head and neck cancer
Colorectal cancer
Lower gastrointestinal cancer
Melanoma
Non-small cell lung cancer
Oesophageal cancer
Head and neck squamous cell carcinoma
Pancreatic cancer
Pancreatobiliary cancer
Gastric cancer
Endometrial cancer
Bladder cancer
Male genital cancers
Prostate cancer
Colorectal adenocarcinoma
Gastric carcinoma
Gastroesophageal junction adenocarcinoma
Hepatobiliary cancer
Hepatocellular carcinoma
Clear cell renal cell carcinoma
Kidney cancer
Urothelial carcinoma
Breast adenocarcinoma
Triple-negative breast cancer
Exocrine pancreatic cancer
Pancreatic adenocarcinoma
Epithelial Ovarian Cancer
High-grade serous carcinoma of the ovary, fallopian tube, and peritoneum
Ovarian adenocarcinoma
Mucosal melanoma
Sarcoma
Mesothelioma
Pleural mesothelioma
Cutaneous melanoma
Skin cancer
High-grade serous ovarian cancer
Ovarian serous carcinoma
Prostate adenocarcinoma
Endometrial carcinoma
Uveal melanoma
Oesophageal squamous cell carcinoma
Renal pelvis cancer
Gastrooesophageal adenicarcoma
Carcinoma
Castrate-resistant prostate cancer
Neuroendocrine carcinoma
Platinum resistant ovarian cancer
Small-cell lung cancer
Small-cell neuroendocrine carcinoma
Cervical clear cell carcinoma
Endometrial clear cell carcinoma
Ovarian clear cell carcinoma
Vaginal and vulvar cancer
Vulval cancer
Vulval clear cell adenocarcinoma
Acral lentiginous melanoma
Biomarker-defined solid tumour
Cutaneous basal cell carcinoma
Cutaneous squamous cell carcinoma
Fallopian tube cancer
MSI-H/dMMR solid tumour
Merkel cell carcinoma
Non-melanoma skin cancer
Non-squamous non-small-cell lung cancer
Peritoneal cancer
Primary peritoneal serous carcinoma
Squamous non-small-cell lung cancer
dMMR solid cancer
Microsatellite stable colorectal cancer
Non-microsatellite instability-high colorectal cancer
Central nervous system cancer
Glioblastoma
Glioma
High-grade glioma
Malignant glioma
Neurological cancer
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy